Immunotech Biopharm (永泰生物) IPO: Behind the Curve in Cell Therapy
Immunotech Biopharma, a cell therapy focused healthcare company, launched book building to raise up to USD 142 million to list in Hong Kong. In our...
622 Views
ECM Weekly (7 June 2020) - JD & NetEase HK Bookbuild, Burning Rock & Nongfu Spring Valuation
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Hong Kong...
369 Views
Legend Biotech (传奇生物) IPO Trading: +27% Upside from Pricing
Legend Biotech, a leading CAR-T player, priced at USD 23/ADS and raised USD 423 million. The stock will start trading today. In this note, we will...
402 Views
Legend Biotech IPO: Pass on Valuation
Legend Biotech (LEGN US) is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...
416 Views
Legend Biotech (传奇生物) Pre-IPO: A Good Deal for the Promising CAR-T
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, started book building to raise up to USD 368 million via an IPO. The company has a...
366 Views